Smith Justin Adam 4

What Happened

• Justin Adam Smith, a director of Journey Medical Corp (DERM), was granted 50,000 restricted stock units (RSUs) on July 1, 2026. The Form 4 reports the grant at $0.00 per share (total $0 on the form), reflecting an award rather than a cash purchase or sale. This is a compensation award that will convert to shares only as the RSUs vest.

Key Details

• Transaction date: July 1, 2026; Filing date: July 2, 2026 (Form 4 accession 0001104659-26-080317).
• Transaction type/code: Award/Grant (A).
• Quantity and reported price: 50,000 RSUs @ $0.00 (total shown $0 on the Form 4).
• Vesting schedule (footnote): 16,666 RSUs vest on July 1, 2029; 16,667 on July 1, 2030; 16,667 on July 1, 2031.
• Shares owned after transaction: not specified in the filing.
• Footnote: filing notes these are restricted stock units that vest over various periods (F1, F2).
• Timeliness: Filing appears timely (filed one day after the grant).

Context

• RSUs are a grant of future shares subject to vesting; they do not represent immediately tradable shares and involve no immediate cash outlay or sale. Such awards are common as long-term compensation and do not in themselves signal a buy/sell decision by the insider.